Background: A major cause of ischemic stroke (IS) worldwide, especially in Asia, is intracranial atherosclerotic stenosis (ICAS), which is also associated with the high risk of recurrent stroke. Objective: The aim of our study was to determine the natural history of symptomatic ICAS ischemic stroke (ICAS IS) patients.
Introduction
Intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke (IS) worldwide and is associated with a high risk of recurrent stroke. [1] [2] [3] It is also known that the rates of ICAS are higher in Asians as compared with Caucasians, with rates noted to be as high as 46% in Chinese patients with IS. 4, 5 Limited data are available in India regarding the incidence of symptomatic ICAS; a study by Kate et al. 6 reported an 11.8% rate of symptomatic ICAS in their IS/transient ischemic attack (TIA) cohort. 6 The SAMMPRIS trial, which randomized IS patients with symptomatic high-grade intracranial stenosis to aggressive medical treatment (AMT) versus AMT plus percutaneous transluminal angioplasty and stenting (PTAS), showed that AMT was superior to PTAS. 7 SAMMPRIS study recommended the use of dual antiplatelet therapy as part of AMT, and to our knowledge, there are no data available in India on natural history (recurrent stroke and mortality) of symptomatic ICAS IS patients following the SAMMPRIS medical management protocol recommendation. There have also been conflicting data with regard to stroke mechanisms that can help predict stroke recurrence in ICAS patients. Data from the SAMMPRIS study showed no difference in lacunar (perforator) versus nonlacunar (hemodynamic and vessel-to-vessel embolic) IS, whereas those from the Chinese study, among others, showed that recurrent rates were higher in patients with perforator lacunar infarcts as compared with nonperforator mechanism infarcts. [8] [9] [10] Thus, the aim of our study was to determine the natural history of symptomatic ICAS IS patients with specific reference to recurrent stroke and death beyond the hyperacute IS phase in the post-SAMMPRIS era.
Methods
We reviewed the charts of all the patients who were seen at Vadodara Stroke Center (based out of Vadodara Institute of Neurological Sciences, a tertiary care hospital specifically focused on the treatment of neurological and neurosurgical patients) with a diagnosis of AIS and TIA attributed to 50%-99% stenosis of a major intracranial artery (internal carotid, middle cerebral, or vertebral artery) during the period of January 2014 to June 2016. We excluded cases of acute IS where there was evidence of symptomatic extracranial internal carotid or vertebral artery stenosis and IS secondary to a cardiac source of origin. We also excluded patients who died during their initial admission for acute IS. Patients with tandem lesions were also excluded. Follow-up data on recurrent stroke and mortality were collected and analyzed by means of follow-up clinic chart review or telephonic interview. Patients were included in the study if they had a mean follow-up of at least 12 months. For the patients who expired, the mentioned mortality was their historical time of death.
In most of the cases, intracranial stenosis was identified on the basis of the time-of-flight magnetic resonance angiogram (TOF MRA) and/or computed tomography angiogram (CTA), and in 3 cases, it was identified by performing a conventional angiogram. Stenosis was considered to be moderate when it was between 50% and 69%, and severe when it was greater than 70%. 11 We also stratified ischemic lesions into 4 subtypes on the basis of the possible mechanism of IS: perforator, embolic, hemodynamic, and mixed. 12 Most patients received dual antiplatelet therapy, with keeping the low-density lipoprotein (LDL) cholesterol was targeted to level <70 mg/dl. Blood pressure (BP) and diabetes mellitus (DM) were treated as per the American Heart Association secondary prevention guideline. 13 Data were collected from follow-up clinic visit. Telephonic contact was made with the patients who did not follow up in the clinic. The primary endpoint was to measure the unfavorable outcome as defined by recurrent stroke or death from any cause. The favorable outcome was defined by no recurrent stroke or death.
Data were collected for the 2 groups-favorable and unfavorable outcomes-on basic demographics and traditional risk factors such as hypertension, coronary artery disease, DM, tobacco abuse, and hyperlipidemia (defined at LDL >100 mg/dl), and statistical analysis was done. Age and National Institutes of Health Stroke Scale (NIHSS) were the continuous variables, whereas sex, vascular risk factors, imaging lesions (mechanism of stroke), and degree of stenosis were categorical variables. The independent sample t-test was used for the continuous variable, whereas the Fisher exact test was used for the categorical variable. All tests were 2 sided with a significance level of 5%.
Results
A total of 87 patients (83 patients with IS, whereas 4 with TIAs) with symptomatic ICAS fit our inclusion criteria. The mean age of our ischemic cohort was 56 years with male predominance (76%). Basic demographics, risk factors, and imaging characteristics are provided in Table 1 . Hyperlipidemia (68%), hypertension (48%), and tobacco abuse (29%) were the most common risk factors. The stroke mechanism reported was 18.39%, 40.22%, 22.98%, and 18.39% in the perforator, embolic, hemodynamic, and mixed group respectively. Severe stenosis (>70%) was present in 82% of the patients. In the anterior circulation, there were 72% of strokes, whereas in the posterior circulations, there were 28% of strokes. The mean NIHSS was 8.4 for this cohort of patients. Middle cerebral artery was the most involved vessel (50 patients/43 severe stenosis), whereas stenosis in ICA, basilar, and vertebral artery were 8 (5 severe), 22 (17 severe), and 7 (6 severe) respectively. Notes: *For LDL data, N = 74 patients for whom data were available.
The mean follow-up time for the total 87 patients was 24.5 months. A total of 9 patients (10.3%) had an unfavorable outcome in the follow-up period. There were 2 cases of recurrent strokes (2.29%) that occurred at 3 weeks and 2 months respectively since their onset, and 7 deaths (8.04%) were reported. Both cases of recurrent strokes occurred in the anterior circulation. Patients with these recurrent stokes had severe stenosis in the main trunk of the middle cerebral artery, and in both the cases, the initial strokes were hemodynamic in nature, whereas the recurrent strokes were hemodynamic in nature. Of the 7 deaths reported, which occurred at 24, 11, 14, 19, 29, 7, and 8 months respectively, 5 patients had their initial stroke in anterior cerebral arteries (4 of whom had severe stenosis), whereas 2 patients had their initial stroke in posterior cerebral arteries (1 of whom had severe stenosis). Of these, 2 deaths were due to multiorgan failure and acute coronary syndrome, whereas the cause of death in 1 patient could not be ascertained. Two patients who died at home had severe deficits at their initial discharge from the hospital, and as per their family members, they could never recover and were not taken for hospitalization any further.
Total 9 patients had an unfavorable outcome, whereas 78 patients did not have a recurrent IS or death. Table 2 shows the results of univariate analysis that revealed that only the age was a predictor of the unfavorable outcome (P = .0025), whereas hyperlipidemia was present more in patients with the favorable outcome (P = .033). Although there was a tendency for patients with poor outcomes to have a higher NIHSS at their onset of stroke, it did not reach statistical significance. No difference was noted between the favorable and unfavorable outcomes as regards other traditional vascular risk factors, location, or mechanism of stroke or degree of stenosis.
Discussion
Previous studies have shown that recurrent stroke rates vary from 7% to 15%/yr in symptomatic ICAS ISs, and those recurrent events were significant in the early period after the initial stroke. 6, 14, 15 A recent study in an urban setting showed the recurrent stroke risk of approximately 20.2% in symptomatic ICAS CS. 16 However, those studies had varying inclusion criteria, and medical management was also not specifically defined. The Genome Segmentation from IntraChromosomal Associations study had shown recurrent IS in 13.7% of their patients during a mean follow-up of 23.4 months, but this was in the pre-SAMMPRIS era where medical treatment was not defined clearly.
14 A recent study from India showed that the risk of stroke in patients with IS was 15.6% in the first year. 6 However, they included patients in the hyperacute IS stage with the recurrent stroke being 8.9% at 7 days. Long-term results of the SAMMPRIS trial (with the median follow-up of 32.4 months) showed that 15% of patients had a primary endpoint (stroke or death), but Abbreviations: CI, confidence interval; SD, standard deviation; NA, not available; NIHSS, National Institutes of Health Stroke Scale.
Notes: *For LDL, data were missing for 2 patients in the unfavorable group and 11 patients in the favorable group. Analysis for LDL was done using n = 7 and n = 67 for these 2 groups respectively.
that would significantly decrease if their first month primary endpoint of 5.8% is excluded. 17 Besides, the Warfarin-Aspirin Symptomatic Intracranial Disease Trial showed that the risk of recurrent stroke was significantly higher in the patients whose qualifying event for the trial occurred 17 days or fewer before enrolment than those whose qualifying event for the trial occurred more than 17 days before enrolment. 8 To summarize, our data showed an unfavorable outcome in 10.34% of patients with a mean follow-up of 24.5 months and only 2.3% of patients had recurrent strokes. The rate of recurrence was lower than that reported in previous studies that could be attributed to the fact that we specifically excluded patients in their hyperacute stage (hospital admission) and also possibly because most of our patients were strictly on dual antiplatelet therapy and the targeted LDL was less than 70 mg/ dl. Besides, our registry is based out of Vadodara Institute of Neurological sciences, which is a tertiary care neurological hospital and thus there may be fewer patients with other significant vascular comorbidities, for example, history of coronary artery disease was 10% in our patient cohort, which is less than what one would expect in a stroke population. We also excluded recurrent TIAs-considered as an unfavorable outcome-because it would be difficult to elicit a clear history of TIA in the patients whose follow-up data were collected through a telephonic interview. As mentioned previously, the cause of death in 2 patients could not be ascertained, but an unfavorable outcome of 10.34% depicts a "ground level" scenario of the natural history of ICAS IS out in the community beyond the hyperacute stage.
Our study does have limitations. It is a single-center study with a small sample size. Although we were strict in our recommendation of dual antiplatelet agent and targeted LDL, the management of BP, DM, and life-style modification was left to the community physicians. Our neuroimaging criteria regarding the degree of stenosis were determined in most cases by TOF MRA, CTAs in few cases, and angiogram was done in only 2 cases. However, we feel that it reflects in practice in the community at large. Besides, the number of patients with unfavorable outcomes was low, which probably contributed to our not being able to find out major differences between 2 groups of outcomes.
We realize our limitations. But with very limited data available in the post SAMMPRIS era on recurrent strokes based on AMT and the fact that our cohort reflects a reallife ground-level practice in community, we believe that it adds to our knowledge of natural history of ICAS-related IS, specifically in India where data are scarcely available. We feel that it is also important to evaluate outcomes beyond the initial hyperacute stage of stroke (i.e., hospital admission) because the natural history of intracranial stenosis is more likely to be different than the hyperacute stage of IS. Besides, it helps us evaluate the success or failure of secondary prevention of stroke at a community level.
As neuroimaging evolves (eg, the recognition of plaque hemorrhage/embolic signals/ulcerated plaques), we shall enhance our knowledge of natural history of ICAS. We look forward to further studies to determine the best possible management of ICAS patients as technical aspects of neuroimaging and intervention techniques/devices evolve in conjunction with the concept of best medical treatment in the secondary prevention of strokes, including specifically ICAS-related strokes.
